Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla, Charles D Lopez, Eric Van Cutsem, Andres J Muñoz Martin, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek-Yeol Ryoo, J Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla, Charles D Lopez, Eric Van Cutsem, Andres J Muñoz Martin, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek-Yeol Ryoo
Abstract
Purpose: SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma (PDAC).
Patients and methods: SEQUOIA, a randomized, global phase III study, compared FOLFOX with PEG + FOLFOX as second line in gemcitabine-refractory PDAC. Patients were randomly assigned 1:1 (PEG + FOLFOX:FOLFOX) and stratified by prior gemcitabine and region. Eligible patients had only one prior gemcitabine-containing treatment. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), response evaluation per Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, and safety. Exploratory analyses included biomarkers related to immune activation.
Results: Between March 1, 2017, and September 9, 2019, 567 patients were randomly assigned PEG + FOLFOX (n = 283) or FOLFOX (n = 284). Most (94.7%) patients received prior gemcitabine plus nab paclitaxel. OS was similar comparing PEG + FOLFOX versus FOLFOX (median: 5.8 v 6.3 months; hazard ratio = 1.045; 95% CI, 0.863 to 1.265). Also, PFS (median 2.1 v 2.1 months; hazard ratio = 0.981; 95% CI, 0.808 to 1.190) and objective response rate (4.6% v 5.6%) were similar between the treatment arms. Most common (≥ 35%) treatment-emergent adverse events in PEG + FOLFOX versus FOLFOX were thrombocytopenia (55% v 20%), anemia (40% v 16%), fatigue (61% v 45%), neutropenia (39% v 28%), abdominal pain (37% v 29%), nausea (45% v 41%), neuropathy (37% v 38%), and decreased appetite (35% v 31%). Exploratory analyses revealed increases in total IL-18, interferon (IFN)-γ, and granzyme B and decreases in transforming growth factor (TGF)-β with the addition of PEG.
Conclusion: PEG added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory PDAC. Safety findings were consistent as previously observed from PEG with chemotherapy; toxicity was manageable and tolerable. Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.
Trial registration: ClinicalTrials.gov NCT02923921.
Figures
References
- Ducreux M Cuhna AS Caramella C, et al. : Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v56-68, 2015(suppl 5)
- Conroy T Desseigne F Ychou M, et al. : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
- Von Hoff DD Ervin T Arena FP, et al. : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
- Berk V Ozdemir N Ozkan M, et al. : XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 59:2635-2639, 2012
- Chung JW Jang HW Chung MJ, et al. : Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer. Hepatogastroenterology 60:363-367, 2013
- Yoo C Hwang JY Kim JE, et al. : A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658-1663, 2009
- Ghosn M Saroufim A Kattan J, et al. : Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Med Oncol 29:2831-2837, 2012
- Wainberg Z Feeney K Lee MA, et al. : Meta-analysis of OS for pancreatic cancer patients receiving 5-FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy. J Clin Oncol 37, 2019(suppl; abstr 202)
- Piechutta M, Berghoff AS: New emerging targets in cancer immunotherapy: The role of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open 4:e000510, 2019
- Patnaik A Kang SP Rasco D, et al. : Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286-4293, 2015
- Royal RE Levy C Turner K, et al. : Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828-833, 2010
- Laghi L Beghelli S Spinelli A, et al. : Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One 7:e46002, 2012
- Hu ZI Shia J Stadler ZK, et al. : Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations. Clin Cancer Res 24:1326-1336, 2018
- Spits H, de Waal Malefyt R: Functional characterization of human IL-10. Int Arch Allergy Immunol 99:8-15, 1992
- Moore KW de Waal Malefyt R Coffman RL, et al. : Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001
- Mumm JB Emmerich J Zhang X, et al. : IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20:781-796, 2011
- Naing A Papadopoulos KP Autio KA, et al. : Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34:3562-3569, 2016
- Naing A Wong DJ Infante JR, et al. : Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): A multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 20:1544-1555, 2019
- Hecht JR Naing A Falchook GS, et al. : Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). J Clin Oncol 36:4119, 2018
- Sonbol MB Firwana B Wang Z, et al. : Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer 123:4680-4686, 2017
- Naing A Infante JR Papadopoulos KP, et al. : PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell 34:775-791 e3, 2018
- Tangkijvanich P Thong-Ngam D Mahachai V, et al. : Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 13:4345-4349, 2007
- Kawabata T Ichikura T Majima T, et al. : Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92:2050-2055, 2001
- Carbone A Vizio B Novarino A, et al. : IL-18 paradox in pancreatic carcinoma: Elevated serum levels of free IL-18 are correlated with poor survival. J Immunother 32:920-931, 2009
- Yost KE Satpathy AT Wells DK, et al. : Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25:1251-1259, 2019
Source: PubMed